Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml
Urologic Oncology: Seminars and Original Investigations, 07/17/2012
Qi P et al. – Long–term oncological outcomes of patients presenting with low prostate–specific antigen (PSA) were excellent in this study. Compared with PSA 4.1–10 ng/ml, patients presenting with PSA ≤4 ng/ml had better bDFS outcomes. However, there was no difference in long–term outcomes between PSA <2.5 and 2.5–4 ng/ml.